Ryan Sullivan
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (27)
Background Prior studies in patients with BRAF ‐mutant melanoma have shown increased density of tumor infiltrating lymphocytes (TIL) after 2 weeks of BRAF (BRAFi) ± MEK inhibition (MEKi), but did not characterize the functional state or clonal diversity of TIL over time. We evaluated sequential tumor biopsies during therapy to test the hypotheses that BRAF/MEKi would increase TIL to day 29, with increases in IFNγ signatures and T‐cell homing receptor ligands and expansion of functional intratumoral tumor‐reactive CD8 T‐cells and TIL clonality in the tumor microenvironment. Methods Subjects with biopsy‐accessible BRAF ‐mutant advanced melanoma received vemurafenib+/−cobimetinib. Tumor biopsies were obtained at baseline and days 8, 15, and 29 on therapy. Tumors were analyzed by quantitative immunofluorescence (QIF), NanoString, and TCRseq. Results Five patients were enrolled. All had an initial tumor response followed by subsequent progression. In four patients, both CD8 + and CD4 + TIL density increased by day 8 or 15 per QIF and continued to increase at day 29 in two. Gene expression data showed upregulation of genes/pathways associated with immunologic rejection of cancer, including Class I and II MHC expression, antigen processing/presentation, and critical T‐cell attracting chemokines. TCRvβ clonal expansion was observed in 3 patients, but most diminished after day 15. Conclusions Data from this study provides provocative evidence that, while BRAF+/−MEK inhibitor therapy produces an increase in overall and clonal T cell infiltrates, there is limited evidence for generation of new or persistent tumor immunity. Thus, BRAFi/MEKi therapy may enable tumor‐reactive T cells to infiltrate tumors but tumor control does not appear to depend on priming new immune responses.
Year:
2026
Background Immune checkpoint inhibitors (ICIs) have revolutionized melanoma treatment, with programmed cell death protein 1 (PD-1) inhibitors—alone or in combination with cytotoxic T-lymphocyte–associated protein 4 or lymphocyte-activation gene 3 inhibitors—demonstrating significant efficacy. However, there is a critical lack of robust data to determine the optimal sequencing of these therapies for individual patients. In particular, the role of relatlimab+nivolumab (rela/nivo) within treatment sequences remains poorly defined. Choosing the right sequence is strategic, as an inappropriate order may compromise the effectiveness of subsequent treatments and limit long-term benefits. Methods This multicenter retrospective and prospective study evaluated 190 patients across three treatment arms: rela/nivo followed by ipilimumab+nivolumab (ipi/nivo) (arm A, N=40), ipi/nivo followed by rela/nivo (arm B, N=71), and anti-PD-1 followed by rela/nivo (arm C, N=79). The study assessed the impact of treatment sequencing on outcomes including response rate, progression-free survival, and overall survival (OS). Results The overall response rate to second treatment was highest in arm C (30.4%), followed by arm B (28.1%) and arm A (17.5%). Patients with secondary resistance to first-treatment ICIs had better responses to second-treatment ICIs than those with primary resistance, particularly in arm B (p=0026). Median OS from date of first ICI treatment was significantly longer in arms B (40.9 months) and C (42.5 months) compared with arm A (16.3 months). Conclusions Our findings indicate that rela/nivo may remain active following anti-PD-1 or ipi/nivo therapy. Additionally, our results suggest that sequencing ipi/nivo before rela/nivo may yield better outcomes than starting with rela/nivo. Patients who respond to the first combination regimen appear to derive greater benefit from the second. Further efforts are needed to optimize sequencing strategies in advanced melanoma, and future studies should consider the impact of prior treatment outcomes.
Year:
2025
Purpose: We conducted an integrated safety analysis from three clinical studies of tebentafusp, a first-in-class ImmTAC bispecific T-cell engager, which can redirect T cells to target glycoprotein 100–positive cells, in metastatic uveal melanoma. Experimental Design: HLA-A*02:01–positive patients with unresectable or metastatic uveal melanoma enrolled in three clinical trials (IMCgp100-01, IMCgp100-102, and IMCgp100-202) who received ≥1 dose of tebentafusp were included. Safety data were pooled to evaluate the profile, onset, and management of treatment-related adverse events (TRAE). Adverse events of special interest included cytokine release syndrome (CRS), acute skin reactions (ASR), and liver function test elevations. Primary prophylaxis with medications was not permitted. Results: Among 410 tebentafusp-treated patients, the most common TRAE were pyrexia (77%), pruritus (71%), and chills (53%). Most patients experienced CRS (88%), almost always mild (grade 1, 19%) to moderate (grade 2, 67%) in severity, with only 2% experiencing grade 3 ( n = 6) or 4 ( n = 1) CRS. Additionally, 92% had at least one ASR, primarily pruritus and rash, with 21% having a grade 3 event. Onset of CRS and ASR was within 1 to 2 days of infusion and generally reversible with standard interventions. Elevated liver function tests were generally mild and resolved without intervention. Most TRAE occurred following the first few infusions and diminished in frequency and severity with repeated dosing; no cumulative TRAE were detected. Discontinuations due to TRAE were rare (2%); there were no treatment-related deaths. Conclusions: TRAE were consistent with tebentafusp’s mechanism of action, mostly occurred during dose escalation, and were predictable, reversible, and manageable with appropriate surveillance and intervention.
Year:
2025
Attenuation of select TRAE with repeated dosing. Incidence and severity of select TRAE over time for patients with mUM treated with tebentafusp across all studies ( N = 410). A, Weekly incidence of TRAE during the acute phase (1–12 weeks). B, Long-term incidence of TRAE in 3-month intervals up to 30 months, which can be broken down into acute (months 1–3), intermediate (months 4–12), and late phases (>12 months). *Rash, LFT, and MRAE are composite terms for a list of related AE of any grade (Supplementary Table S1).
Year:
2025
Frequency of AESI by maximum grade and kinetics of onset and resolution of AESI. A, Frequency of each AESI by grade. CRS was programmatically graded post hoc according to the ASTCT consensus grading criteria for CRS for patients in studies 102 and 202 ( N = 391). CTCAE grading for treatment-emergent ASR and elevations in LFT for all patients ( N = 410). B and C, Median time to ( A ) onset from the start of the first dose or ( B ) resolution from the start of AESI for CRS, ASR, and LFT elevations. The peak of each curve shows the proportion of patients who developed that AESI. CRS was programmatically graded post hoc according to the ASTCT consensus grading criteria for CRS for patients in studies 102 and 202 ( N = 391). CTCAE grading for treatment-emergent ASR and elevations in LFT for all patients ( N = 410).
Year:
2025
Landmark OS for corticosteroid use within the first 30 days of the first tebentafusp dose. Kaplan–Meier plot of inverse probability of treatment–weighted OS (ATE weights) by corticosteroid use within the first 30 days of the first tebentafusp dose, landmarked at day 30. HR (95% confidence interval), 1.09 (0.67–1.76). ATE, average treatment effects.
Year:
2025
Background Immune checkpoint inhibitors (ICIs) are associated with a 3‐fold risk of atherosclerotic cardiovascular disease (ASCVD). However, the biology of atherosclerosis is different among women and men, and ASCVD risk factors among women treated with an ICI are incompletely understood. This study aimed to identify factors associated with ASCVD in women following ICIs and to characterize plaque progression. Methods In a single‐center retrospective study, clinical and cancer‐related factors were compared among women treated with ICIs who did and did not experience ASCVD. Competing risk analysis estimated the effect of ICIs on cardiovascular risk. In an imaging substudy, the rate of atherosclerotic plaque progression post‐treatment was compared between women and men. Results Among 1188 female patients treated with an ICI, 54 (5%) experienced an ASCVD with a median time to event of 174 days. Patients with ASCVD had a higher prevalence of prior myocardial infarction and coronary revascularization (15% versus 6%, P =0.007) and prior stroke (7% versus 2%, P =0.039). Competing risk analyses, adjusting for cardiovascular risk factors, revealed an almost 3‐fold increased risk of post‐ICI ASCVD in women with prior cardiovascular events (hazard ratio, 2.71 [95% CI, 1.24–5.95]; P =0.013). In an imaging study, the annual rate of plaque progression post‐ICI was 6% for total and 7% for non‐calcified plaque, with similar rates of progression observed in women and men. Conclusions In female patients treated with ICIs, 5% developed an ASCVD, and a history of cardiovascular events was a risk factor. In an imaging study, plaque progressed in a short time frame after ICI therapy.
Year:
2025
Immune checkpoint inhibitors (ICIs) have improved survival of patients with cancer, yet they pose risks of immune-related adverse events (irAEs). ICI-induced insulin-dependent diabetes mellitus (ICI-DM) is a life-threatening and life-altering irAE. Previously, we reported a high incidence of a germline missense variant in NLRC5 , a key class I transcription activator, among patients with ICI-DM compared with similarly treated patients who did not develop ICI-DM. Our purpose was to validate this finding in additional ICI-treated patients and study effects of the NLRC5 variant on expression of class I major histocompatibility complex (MHC) antigen presentation genes. We assessed the prevalence of the C>T missense variant at chr16:57 025 515 ( NLRC5Pro191Leu ) in germline DNA from an additional 33 patients with ICI-DM and in patients with ICI-induced colitis (n=15), ICI-induced hypothyroidism (n=19) and ICI-induced hypophysitis (n=17). The 1,000 Genomes Project was used for comparison. We assessed peripheral blood mononuclear cells from 16 individuals with or without the NLRC5 variant, studying expression of NLRC5 and select downstream target genes, before and after stimulation with interferon-γ. We validated the higher prevalence of NLRC5Pro191Leu in a non-overlapping cohort of patients with ICI-DM compared with the general population (51.5% vs 12.8%, p<0.0001). The prevalence of NLRC5Pro191Leu in ICI-induced colitis or thyroiditis patients did not significantly differ from the general population, while the prevalence in ICI-induced hypophysitis was somewhat higher (21.6%, p=0.048). We found greater increases in messenger RNA expression of NLRC5 (p=0.007), TAP1 (p=0.0002), B2M (p=0.0005), HLA-G (p=0.04), PSMB8 (p=0.03) and PSMB9 (p=0.01) in NLRC5Pro191Leu cells stimulated with interferon-γ compared with NLRC5 WT cells. A similar trend was observed for HLA-A (p=0.09). We confirm the significantly higher prevalence of the NLRC5Pro191Leu variant in patients with ICI-DM relative to the general population. This abundance appears to be unique to patients who develop ICI-DM or hypophysitis on ICIs, underscoring its potential involvement in the pathogenesis of these endocrinopathies. The effects of this NLRC5 variant on class I MHC regulators suggest a mechanistic connection between the variant and development of ICI-DM. Further work is warranted to determine whether class I MHC molecules can be modulated in patients with the NLRC5Pro191Leu variant requiring ICIs.
Year:
2025
PURPOSE Immunotherapy has improved survival for patients with melanoma and non–small cell lung cancer (NSCLC). Yet, as responses vary widely, immunotherapy also introduces challenges in prognostic communication. In this study, we sought to explore how patients and caregivers learned about the goal of immunotherapy and their experience of living with uncertainty. MATERIALS AND METHODS We conducted a qualitative study of patients with stage III or IV melanoma or stage IV NSCLC within 12 weeks of initiating or 12 months of discontinuing immunotherapy, and their caregivers. We conducted in-depth interviews with participants to explore how they learned about immunotherapy from oncology clinicians and how they experienced uncertainty. We used a framework approach to analyze interview transcripts and synthesized concepts into themes. RESULTS Forty-two patients and 10 caregivers participated; median age was 67 years and most were male (68%), white (95%), married (61%), and had melanoma (62%). We identified four themes: (1) the oncology team shaped participants' hopeful expectations of immunotherapy, including as a potential cure among those with melanoma; (2) distress related to prognostic uncertainty particularly affected patients who experienced toxicity or progressive disease; (3) patients who did not have long-term responses experienced overwhelming disappointment; and (4) some patients and caregivers had conflicting preferences for prognostic information. Participants provided suggestions to improve education and underscored unmet psychosocial needs. CONCLUSION Patients and caregivers held optimistic expectations of immunotherapy, which resulted in heightened disappointment among the subset with progression or toxicity. Clinicians should elicit information preferences of both patients and caregivers, as these may be disparate. Our results highlight the need to optimize prognostic communication and support for living with uncertainty among patients receiving immunotherapy.
Year:
2025
Purpose: Eganelisib (IPI-549) is a first-in-class, orally administered, highly selective PI3Kγ inhibitor with antitumor activity alone and in combination with programmed cell death protein 1/ligand 1 (PD-1/PD-L1) inhibitors in preclinical studies. This phase 1/1b first-in-human, MAcrophage Reprogramming in Immuno-Oncology-1 (NCT02637531) study evaluated the safety and tolerability of once-daily eganelisib as monotherapy and in combination with nivolumab in patients with solid tumors. Patients and Methods: Dose-escalation cohorts received eganelisib 10–60 mg as monotherapy ( n = 39) and 20–40 mg when combined with nivolumab ( n = 180). Primary endpoints included incidence of dose-limiting toxicities (DLT) and adverse events (AE). Results: The most common treatment-related grade ≥3 toxicities with monotherapy were increased alanine aminotransferase (ALT; 18%), aspartate aminotransferase (AST; 18%), and alkaline phosphatase (5%). No DLTs occurred in the first 28 days; however, toxicities meeting DLT criteria (mostly grade 3 reversible hepatic enzyme elevations) occurred with eganelisib 60 mg in later treatment cycles. In combination, the most common treatment-related grade ≥3 toxicities were increased AST (13%) and increased ALT and rash (10%). Treatment-related serious AEs occurred in 5% of monotherapy patients (grade 4 bilirubin and hepatic enzyme increases in one patient each) and 13% in combination (pyrexia, rash, cytokine release syndrome, and infusion-related reaction in ≥2 patients each). Antitumor activity was observed in combination, including patients who had progressed on PD-1/PD-L1 inhibitors. Conclusions: On the basis of the observed safety profile, eganelisib doses of 30 and 40 mg once daily in combination with PD-1/PD-L1 inhibitors were chosen for phase 2 study.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (50)
caroline robert
- Directeur de l’équipe «Résistance thérapeutique» dans l’Unité INSERM U 981 : Biomarqueurs prédicteurs et nouvelles stratégies moléculaires en thérapeutique anticancéreuse
Université de Paris Faculté de Santé
Joan Brugge
Professor
Harvard University
Govind Warrier
Assistant Professor of Oncology
Johns Hopkins University
Lara Traeger
Associate Professor
University of Miami
Georgina V. Long
University of Sydney
Joseph J. Sacco
Senior Lecturer Clinical
University of Liverpool
Khanh Do
Assistant Professor of Medicine
Dana-Farber Cancer Institute
Jessica C. Hassel
Heidelberg University
Takami Sato
Professor
Thomas Jefferson University
Nora Zizlsperger
-
Daniel Zlotoff
Harvard University
Viktor Adalsteinsson
Group Leader
Broad Institute
Reinhard Dummer
University Hospital of Zurich
Alexander M. Menzies
University of Sydney
Christine Lian
Dermatopathologist/Associate Professor
Brigham and Women's Hospital
Bartosz Chmielowski
Ronald Reagan UCLA Medical Center
Marcus Butler
University Health Network
Harriet Kluger
Yale University School of Medicine
John Kirkwood
Distinguished Service Professor of Medicine
University of Pittsburgh
Allison Betof Warner
Assistant Professor, Director of Melanoma Medical Oncology, Director of Solid Tumor Cellular Therapy
Stanford University
Ezra Cohen
Professor of Medicine
Moores Cancer Center, UC San Diego Health
Elizabeth Buchbinder
Harvard University
Béla Merkely
Semmelweis University
Genevieve Boland
Chair of Surgery
Medical College of Wisconsin
Anthony M. Joshua
Head of Department
University Health Network
Michael A. Postow
Weill Cornell Medical College
F. Dimitriou
Attending Physician, Head of Skin Cancer Center
University Hospital of Bern
Alexandra Ikeguchi
Associate Professor
The University of Texas MD Anderson Cancer Center
Jeffrey Clark
Associate Professor
Harvard University
Alexander Noor Shoushtari
Memorial Sloan Kettering Cancer Center
Paul Nathan
University College London
Jennifer A. Wargo
The University of Texas MD Anderson Cancer Center
Elizabeth Burton
The University of Texas MD Anderson Cancer Center
David S. Hong
The University of Texas MD Anderson Cancer Center
Isabella C Glitza Oliva
Professor
The University of Texas MD Anderson Cancer Center
Sebastian Ochsenreither
Charité - Universitätsmedizin Berlin
Christine Spencer
Parker Institute for Cancer Immunotherapy
David Liu
Assistant Professor
Dana-Farber Cancer Institute
Thuy Tran
Assistant Professor
Yale University Yale Cancer Center
Zoltán V Varga
junior group leader
Semmelweis University
Jedd Wolchok
Director
Weill Cornell Medicine
Piotr Rutkowski
Narodowy Instytut Onkologii im Marii Skłodowskiej-Curie Państwowy Instytut Badawczy w Warszawie
Mark Middleton
University of Oxford
Julie Densmore
Parker Institute for Cancer Immunotherapy
Christine Peterson
Associate Professor
Rice University
Paolo Antonio Ascierto
Full Professor
Università degli Studi di Napoli Federico II
Colin Weekes
Associate Professor
Massachusetts General Hospital
Nadim Ajami
Executive Director
The University of Texas MD Anderson Cancer Center
Jennifer Temel
Massachusetts General Hospital
Ines Pires da Silva
Medical Oncologist
University of Sydney
Make your next move.
Prepare your application
Review drafts before you send them.